VC-backed Spero Therapeutics files for IPO
Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company focused on developing treatments for bacterial infections, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company is planning on trading the stock on the NASDAQ under the ticker symbol "SPRO." BofA Merrill Lynch, Cowen and Stifel will serve as lead underwriters. Spero's backers include GV, RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.
9 October 2017•2 mins read
